Search | Clinical Trials Finder

Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: cetuximab, paclitaxel, bevacizumab; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Non Small Cell Lung Cancer
Interventions: Pemetrexed, Cisplatin, Necitumumab; Drug · Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 633 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: Nyack, New York

Conditions: Lung Cancer, Radiation Toxicity
Interventions: flaxseed, placebo; Dietary Supplement · Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 120 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-Small-Cell Lung Cancer
Interventions: Nivolumab, Ipilimumab, Platinum Doublet Chemotherapy; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 29
States / cities: San Diego, California • Plainville, Connecticut • Weston, Florida + 19 more

Conditions: Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Vorinostat; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 13
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 10 more

Conditions: Non-small Cell Lung Cancer, NSCLC
Interventions: Tislelizumab, Ociperlimab, Pembrolizumab, Placebo; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 669 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 9
States / cities: Fullerton, California • Los Angeles, California • Ocala, Florida + 6 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: ABT-510/Thrombospondin-1 mimetic, Carboplatin/Taxol; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 4
States / cities: Miami, Florida • Chicago, Illinois • Memphis, Tennessee + 1 more

Conditions: Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions: Ceralasertib, Durvalumab, Docetaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 27
States / cities: Mobile, Alabama • Chandler, Arizona • Los Alamitos, California + 24 more

Conditions: ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma, Progressive Disease, ROS1 Gene Rearrangement, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer
Interventions: Binimetinib, Brigatinib; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Elastography, Multigated Acquisition Scan, Necitumumab, Osimertinib; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 15
States / cities: Duarte, California • Palo Alto, California • Sacramento, California + 7 more

Conditions: Lung Cancer
Interventions: carboplatin, docetaxel, gemcitabine hydrochloride; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lung Cancer
Interventions: gold sodium thiomalate, gene expression analysis, fluorine F 18 fluorothymidine, mass spectrometry, pharmacological study; Drug · Genetic · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions: 3-Dimensional Conformal Radiation Therapy (3D-CRT), Docetaxel, Gemcitabine, Intensity-Modulated Radiation Therapy (IMRT), Pemetrexed Disodium, Stereotactic Body Radiation Therapy (SBRT), Erlotinib Hydrochloride, Pembrolizumab; Radiation · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 296
States / cities: Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 228 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Taletrectinib, Placebo; Drug
Lead sponsor: Nuvation Bio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 12
States / cities: Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 9 more

Conditions: Lung Cancer
Interventions: laboratory biomarker analysis; Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Small Cell Lung Cancer
Interventions: Tetrathiomolybdate; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Non-small Cell Lung Cancer Metastatic
Interventions: Nivolumab + Plinabulin; Drug
Lead sponsor: Lyudmila Bazhenova, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Lung Cancer
Interventions: cetuximab, vinflunine; Biological · Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Burlington, North Carolina • Chapel Hill, North Carolina

Conditions: Non-Small Cell Lung Cancer
Interventions: Bevacizumab, Erlotinib, Pemetrexed; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 70 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Malignancy, Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Testicular Cancer, Thymoma, Ovarian Cancer, Osteosarcoma
Interventions: palifosfamide-tris; Drug
Lead sponsor: Alaunos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Indianapolis, Indiana • Lafayette, Indiana • Muncie, Indiana + 1 more

Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: tanespimycin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Carcinoma, Non-small Cell Lung
Interventions: Genomic profile by FoundationOne, Genomic profile by other methods; Genetic
Lead sponsor: Cota Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions: MCLA-129, Osimertinib, Chemotherapy; Drug
Lead sponsor: Merus B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 4
States / cities: Orange, California • Nashville, Tennessee • West Valley City, Utah + 1 more

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sotorasib, Trastuzumab Deruxtecan; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Sacramento, California • Tampa, Florida • Wesley Chapel, Florida + 4 more

Search by objective public record fields.

S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer

First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin

Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy

Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Gold Sodium Thiomalate in Treating Patients With Advanced Non-Small Cell Lung Cancer

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Study of Tumor Samples From Patients With Lung Cancer

Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer

Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC

Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer

Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

Genomic Profiling in Previously Untreated Metastatic Non-small Cell Lung Cancer

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation